Our Pipeline

Aims to address ATTRv and ATTRwt, both polyneuropathy and cardiomyopathy, with a single course of treatment

Aims to reduce plasma kallikrein activity to prevent excess bradykinin production leading to HAE attacks after a single course of treatment

Aims to address AATD-associated liver disease

Aims to address AATD-associated lung disease

Intellia and Regeneron are co-developing potential hemophilia B CRISPR/Cas9-based treatments using their jointly developed targeted transgene insertion capabilities.

Intellia and Regeneron are co-developing potential hemophilia A CRISPR/Cas9-based treatments using their jointly developed targeted transgene insertion capabilities.

Alpha-1 antitrypsin deficiency (AATD), primary hyperoxaluria (PH) and undisclosed indications